Update on Eklira® (aclidinium bromide) for chronic obstructive pulmonary disease (COPD): Positive results in a short-term comparative trial and announcement of new Phase III studies

Barcelona, October 20 th , 2009 : Almirall, S.A. (ALM.MC) today announced the completion of a short-term Phase II study comparing aclidinium twice daily (BID) vs tiotropium and placebo [1] as well as the completion of the enrolment of a larger Phase III three-month study with two different BID doses of Eklira ® vs placebo in patients with moderate to severe COPD [2] . «The positive outcomes from a short-term Phase II comparative study with Eklira ® BID vs tiotropium and placebo 1 , confirm Almirall and Forest decision to add to the ongoing twice daily development programme new Phase III clinical studies, including one of three months and one of six months duration with aclidinium vs placebo» said Per-Olof Andersson, Executive Director R&D at Almirall . Both studies will investigate the effects of aclidinium bromide in patients with moderate to severe COPD using a BID dosing regimen. Almirall and Forest Laboratories, Inc. (NYSE:FRX) plan to disclose the results of both the short-term comparative Phase II study and the ongoing three-month Phase III study in the first quarter of 2010.

The release as fetched from its publisher. almirall.com ↗